Toward harmonized phenotyping of human myeloid-derived suppressor cells by flow cytometry: results from an interim study

[1]  Cliburn Chan,et al.  Data analysis as a source of variability of the HLA-peptide multimer assay: from manual gating to automated recognition of cell clusters , 2015, Cancer Immunology, Immunotherapy.

[2]  S. H. van der Burg,et al.  Harmonisation of short-term in vitro culture for the expansion of antigen-specific CD8+ T cells with detection by ELISPOT and HLA-multimer staining , 2014, Cancer Immunology, Immunotherapy.

[3]  V. Bronte,et al.  Myeloid‐derived suppressor cell heterogeneity in human cancers , 2014, Annals of the New York Academy of Sciences.

[4]  V. Bronte,et al.  Complexity and challenges in defining myeloid-derived suppressor cells. , 2014, Cytometry. Part B, Clinical cytometry.

[5]  M. Jaimes,et al.  A harmonized approach to intracellular cytokine staining gating: Results from an international multiconsortia proficiency panel conducted by the Cancer Immunotherapy Consortium (CIC/CRI) , 2013, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[6]  B. Zhang,et al.  Increased CD14+HLA-DR-/low myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients , 2013, Cancer Immunology, Immunotherapy.

[7]  S. Lang,et al.  Granulocytic myeloid-derived suppressor cells are cryosensitive and their frequency does not correlate with serum concentrations of colony-stimulating factors in head and neck cancer , 2013, Innate immunity.

[8]  S. Wong,et al.  Increased Myeloid-Derived Suppressor Cells in Gastric Cancer Correlate with Cancer Stage and Plasma S100A8/A9 Proinflammatory Proteins , 2013, The Journal of Immunology.

[9]  S. H. van der Burg,et al.  Serum-free freezing media support high cell quality and excellent ELISPOT assay performance across a wide variety of different assay protocols , 2012, Cancer Immunology, Immunotherapy.

[10]  B. Schilling,et al.  Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples. , 2012, Journal of immunological methods.

[11]  Hiroaki Tanaka,et al.  Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival , 2012, Nature Medicine.

[12]  S. Lang,et al.  Neutrophils and granulocytic myeloid-derived suppressor cells: immunophenotyping, cell biology and clinical relevance in human oncology , 2012, Cancer Immunology, Immunotherapy.

[13]  Cedrik M. Britten,et al.  Harmonization of the intracellular cytokine staining assay , 2012, Cancer Immunology, Immunotherapy.

[14]  D. Gabrilovich,et al.  Coordinated regulation of myeloid cells by tumours , 2012, Nature Reviews Immunology.

[15]  A. Rosato,et al.  A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. , 2011, Blood.

[16]  P. Zabel,et al.  Myeloid‐derived suppressor cells in the peripheral blood of cancer patients contain a subset of immature neutrophils with impaired migratory properties , 2011, Journal of leukocyte biology.

[17]  M. Roederer,et al.  Data analysis in flow cytometry: The future just started , 2010, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[18]  S. Mocellin,et al.  IL4Rα+ Myeloid-Derived Suppressor Cell Expansion in Cancer Patients1 , 2009, The Journal of Immunology.

[19]  L. Ben-Porat,et al.  Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium , 2009, Cancer Immunology, Immunotherapy.

[20]  M. Atkins,et al.  Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. , 2009, Cancer research.

[21]  P. Dahm,et al.  Reversal of Myeloid Cell–Mediated Immunosuppression in Patients with Metastatic Renal Cell Carcinoma , 2008, Clinical Cancer Research.

[22]  M. Nishimura,et al.  Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy , 2008, Cancer Immunology, Immunotherapy.

[23]  L. Mariani,et al.  Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Ingo Fricke,et al.  All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. , 2006, Cancer research.

[25]  S. Signoretti,et al.  Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. , 2005, Cancer research.

[26]  D. Gabrilovich,et al.  Immature myeloid cells and cancer-associated immune suppression , 2002, Cancer Immunology, Immunotherapy.

[27]  O. Finn,et al.  Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. , 2001, Cancer research.

[28]  Nicholas R. English,et al.  Increased Production of Immature Myeloid Cells in Cancer Patients: A Mechanism of Immunosuppression in Cancer1 , 2001, The Journal of Immunology.